Shark liver oils market was valued at $156.2 million in 2025 and is expected to reach $263.6 million by 2035, registering a CAGR of 5.5% during the forecast period from 2026 to 2035. Recent developments in environmental regulation and ingredient innovation are influencing dynamics across the Global Shark Liver Oils market. In December 2025, international conservation agreements under the Convention on International Trade in Endangered Species of Wild Fauna and Flora (CITES) were strengthened to enhance protection for endangered sharks, including deep-sea species traditionally harvested for high-value liver oil. This increased protection is expected to prompt greater sustainability scrutiny and supply chain adjustments among producers and suppliers within the shark liver oils ecosystem.

The regenerated cellulose market was valued at $21.0 billion in 2025 and is projected to reach $40.5 billion by 2035, expanding at a CAGR of 6.9% during the forecast period from 2026 to 2035. The market is increasingly driven by industry-wide sustainability commitments that are reshaping material choices across apparel, home textiles, hygiene, and technical segments. Textile producers and brand owners are shifting away from fossil-based synthetics toward biodegradable, renewable alternatives to reduce environmental impact and align with climate goals. This transition is supported by regulatory pressure, corporate disclosure requirements on emissions, and rising consumer demand for sustainable fibers,

The PVC resuscitation mask market was valued at $1.20 billion in 2025 and is expected to reach $2.16 billion by 2035, registering a CAGR of 6.2% over the forecast period from 2026 to 2035. Emergency medical response systems have become more structured and widely implemented globally, creating a clear demand driver for PVC resuscitation masks as essential life-saving equipment. Healthcare authorities and ambulance services are standardizing emergency care protocols, which routinely specify bag-valve-mask (BVM) devices with PVC masks for airway management in cardiac arrest and respiratory distress situations. Training of first responders and expansion of prehospital care units have increased the volume of PVC resuscitation masks procured by hospitals, EMS providers, and community health programs. 

Printing inks market was valued at $26.6 billion in 2025 and is projected to reach $38.5 billion by 2035, expanding at a CAGR of 3.8% over the forecast period from 2026 to 2035. Environmental sustainability is driving growth in the global printing inks market as manufacturers and brand owners shift toward low?impact ink formulations that meet stricter regulatory standards and evolving customer expectations. Regulatory frameworks in major markets are encouraging the adoption of water?based and UV?curable inks that emit significantly fewer volatile organic compounds (VOCs), while corporations pursue greener supply chains in packaging and commercial printing. Regulatory pressure and consumer sustainability preferences are influencing procurement decisions, prompting ink producers to innovate and expand eco?friendly portfolios. This focus on sustainability is reinforcing investment in R&D, enhancing product diversification, and supporting long?term market expansion across key regions, including Europe and North America.

Potassium sulphate market was estimated at $2.20 billion in 2025 and is projected to reach $3.47 billion by 2035, expanding at a CAGR of 4.8% over the forecast period from 2026 to 2035. The global potassium sulphate market is being propelled by a clear agricultural shift toward chloride-free nutrient solutions for high-value and chloride-sensitive crops. Potassium sulphate (also known as sulfate of potash) delivers essential potassium and sulfur without the negative effects of chloride ions that can harm crop roots and soil health, making it the preferred fertilizer for fruits, vegetables, tobacco, and other sensitive horticultural crops. This driver is reinforced by official fertilizer quality standards recognizing SOP’s chloride limitation and sulfur content, which supports improved crop outcomes relative to alternative potash fertilizers.

Polyethylene furanoate market was valued at USD 38.3 million in 2025 and is projected to reach USD 78.2 million by 2035, registering a CAGR of 7.5 percent over the forecast period from 2026 to 2035. The PEF market is gaining traction as material certification for recycling compatibility increases confidence among converters, brand owners, and regulators. Recent endorsements and approvals in key markets confirm that PEF can be integrated into existing polyethylene terephthalate (PET) recycling streams without disruption, reducing barriers to commercial uptake and supporting sustainable packaging goals. These developments enable PEF to function not only as a standalone monolayer polymer but also as a barrier layer in multilayer PET bottles, aligning with circular economy objectives and reducing end?of?life waste concerns. 

Payment gateway market was estimated at $25.7 billion in 2025 and is expected to grow to $69.9 billion by 2035, registering a CAGR of 10.7% over the forecast period from 2026 to 2035. The surge in digital wallet usage is emerging as a central driver of growth in the global payment gateway market, fundamentally reshaping how consumers and merchants transact. According to the Worldpay Global Payments Report 2024, digital wallets delivered approximately $13.9 trillion in global transaction value in 2023, accounting for half of all e?commerce payments and 30% of point?of?sale consumer spend, and are projected to exceed $25 trillion by 2027 across online and in?store channels, highlighting their rising dominance in payment behavior. 

Overactive Bladder (OAB) therapeutics market was valued at $3.53 billion in 2025 and is projected to reach $4.86 billion by 2035, expanding at a CAGR of 3.4% over the forecast period from 2026 to 2035. The growing prevalence of Overactive Bladder (OAB) globally is a principal driver of demand for therapeutics, directly expanding the addressable patient population for both anticholinergic agents and beta-3 adrenoreceptor agonists. A rigorous meta-analysis incorporating more than 610,000 participants estimates the global prevalence of OAB at around 20%, indicating that a substantial share of adults experience symptoms requiring clinical management. Over the past two decades, prevalence has climbed from roughly 18.1% to 23.9%, reflecting demographic shifts and increasing risk factor burdens such as aging and obesity.

The optical spectrum analyzer market was valued at $480.2 million in 2025 and is projected to reach $822.9 million by 2035, expanding at a CAGR of 5.7% over the forecast period from 2026 to 2035. The growth of the global optical spectrum analyzer market is increasingly driven by the rapid expansion of fiber?optic infrastructure and high?speed optical communication deployment. As broadband infrastructure evolves to support 5G backhaul, cloud services, and data center interconnects, service providers and equipment manufacturers require more precise spectral measurement and troubleshooting tools, positioning optical spectrum analyzers as essential test?and?measurement equipment. High?quality, gigabit?class broadband and fiber?to?the?home upgrades are prioritised in both developed and emerging economies, strengthening demand for advanced optical characterization. 

Opioid induced constipation (OIC) drug market was valued at $953.2 million in 2025 and is projected to reach $1,463.9 million by 2035, growing at a CAGR of 4.5% during the forecast period from 2026 to 2035. The market is being driven by the increasing clinical recognition of OIC as a significant adverse effect of opioid therapy, especially in populations with chronic pain or cancer. As prescribing of opioids persists for pain management, clinicians are more frequently identifying and documenting constipation directly linked to opioid use, which in turn increases demand for targeted therapeutic interventions. This trend has expanded the role of peripherally acting mu?opioid receptor antagonists (PAMORAs) and other OIC?specific agents in treatment protocols, creating clearer pathways for product adoption and reimbursement.